Researchers have created BioCog, a self-administered digital cognitive test designed for primary care. The test assesses memory, attention and processing speed, identifying patients with cognitive imp...

A Swedish-led study validated a self-administered digital cognitive test (BioCog) in primary care, showing it can accurately detect objective cognitive impairment before blood biomarkers are applied. ...

A brief, self-administered digital cognitive test, in combination with a blood test, accurately detects clinical Alzheimer’s disease in primary care.

Read the full paper: Prediction and risk evaluation of delirium after surgery in older patients: development and internal validation of an algorithm from the prospective BioCog cohort study

Read the full paper: Associations between blood cholin-esterase activity and postoperative basal forebrain cholinergic system atrophy: A secondary analysis of the BioCog cohort with exploration of potential mechanisms

Un nuevo test digital para detectar la enfermedad de Alzheimer de manera temprana busca cambiar el modo en que se identifican los primeros síntomas en los centros de salud. El desarrollo fue realizado por investigadores de la Universidad de Lund en Suecia y otras instituciones. Consiste en una herramienta, llamada BioCog, que permite a los médicos generalistas saber qué pacientes podrían necesitar estudios más avanzados.

An 11-minute iPad test, paired with a blood screen, detects Alzheimer’s with 90% accuracy and outperforms doctors in primary care settings.

São Paulo — InkDesign News — Uma pesquisa conduzida por cientistas da Universidade de Lund revela que um novo teste digital de cognição, chamado BioCog, pode

Investigadores de Suecia desarrollaron una herramienta digital llamada BioCog y difundieron su evaluación en la revista Nature Medicine. Cómo su uso podría facilitar la derivación de pacientes y evitar estudios innecesarios

Investigadores de Suecia desarrollaron una herramienta digital llamada BioCog y difundieron su evaluación en la revista Nature Medicine. Cómo su uso podría facilitar la derivación de pacientes y evitar estudios innecesarios

A proof-of-concept study by a team of Lund University scientists shows that their brief, self-administered digital cognitive test — named BioCog — can detect cognitive impairment and, when combined with a blood test, accurately identify clinical Alzheimer’s disease in primary care. Alzheimer’s disease is the most common cause of dementia, characterized by depositions of amyloid-beta, aggregated tau and progressive neurodegeneration. The clinical syndrome of Alzheimer’s disease typically starts with subjective cognitive decline, in which individuals report memory problems and/or other cognitive difficulties but perform normally on cognitive tests. This phase is followed by mild cognitive impairment, marked by objective cognitive symptoms, and later by dementia, characterized by clear functional deficits in activities of daily living.

A tablet-based cognitive test completed by patients themselves has proven more accurate than primary care physicians at identifying who needs further testing for Alzheimer's disease, according to new research that could reshape how the condition is diagnosed in doctor's offices. The Swedish study, published in Nature Medicine, found that their BioCog digital test achieved 85% accuracy in detecting cognitive impairment among 403 primary care patients with memory concerns.